Increased Plasma Transforming Growth Factor-β1 in Migraine

Authors

  • Kumiko Ishizaki MD, PhD,

  • Takao Takeshima MD, PhD,

  • Yoko Fukuhara MD, PhD,

  • Haruko Araki MD,

  • Kazuhiro Nakaso MD, PhD,

  • Masayoshi Kusumi MD, PhD,

  • Kenji Nakashima MD, PhD


  • From the Department of Neurology, Institute of Neurological Sciences, Faculty of Medicine, Tottori University, Yonago, Japan.

Address all correspondence to Dr. Takao Takeshima, Department of Neurology, Institute of Neurological Sciences, Faculty of Medicine, Tottori University, 36-1 Nishimachi, Yonago 683-8504, Japan.

Abstract

Background and Objectives.—Migraine is characterized by the peripheral and central sensitization of pain perceptive neural systems, and neurogenic inflammation is a key step in the development of migraine headache. We focused on transforming growth factor-β1 (TGF-β1), which is a multifunctional proinflammatory cytokine. To address the possibility of TGF-β1 involvement in migraine, we investigated the plasma level of TGF-β1 in patients with migraine headache during headache-free periods.

Subjects and Methods.—Sixty-eight subjects with migraine participated: 23 with migraine with aura (MWA) and 45 without aura (MWoA). We recruited 58 healthy subjects without headache as controls. In addition, we examined 12 subjects with episodic tension-type headache. Platelet poor plasma (PPP) was obtained from subjects during headache free-periods. TGF-β1 levels in PPP were determined by enzyme-linked immunosorbent assay.

Results.—The TGF-β1 level in PPP was 2.62*± 0.23 (mean ± SE) ng/mL in migraine, 2.08 ± 0.20 ng/mL in tension-type headache, and 1.80 ± 0.09 ng/mL in controls (P= .007, ANOVA; *P < .01, post hoc tests vs. the controls).

Conclusion.—TGF-β1 in PPP was significantly increased in patients with migraine during headache-free periods. TGF-β1 may play some role in the development of migraine headache.

Ancillary